All News

acr_session2.jpeg

EULAR 2023 – Day 2 Report

d Jack Cush, MD

Day 2 at the international EULAR Congress meeting is always bigger and busier. There were sessions on JIA therapies, crystal arthritis, novel drugs for SLE and Sjogren's, early RA and preclinical RA interventions, IgG4 disease, osteoporosis and the growth and application of artificial intelligence in medicine and rheumatology.

Read Article
question-mark-1872634_640.jpg

Better at Predicting RA from MRI: Humans or Computers?

d David Liew, FRACP

An artificial intelligence model to assess pre-RA hand MRIs has confirmed what human readers have known before: that bone marrow edema and tenosynovitis are objectively the best predictors of future RA development in patients with clinically suspect arthralgias or undiffer

Read Article
lupus_0.jpg

The future of lupus treatment is oral therapies?

d Janet Pope, MD, MPH, FRCPC

There has been an explosion of trials in SLE, including nonrenal and glomerulonephritis studies. But, what about the JAKis and Tyk2 oral drugs in SLE?

Read Article
Stills,continuum

AOSD: Young vs. Elderly Onset

d Bella Mehta, MBBS, MS

Adult onset still's disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million.

Read Article
#lupus Phase 1 data #EULAR2023 humanised, afucosyl IgG1 antibody against CXCR5 – receptor on B cells and bonafide T follicular helper(Tfh) and circulating T follicular helper-like(cTfh) cells – Potent, tolerated and caused depletion of cells in SLE and RA. Abst#AB0511 @rheumnow

Bella Mehta bella_mehta ( View Tweet)

bone complications #SLE – imp to maintain vitamin D levels! Osteonecrosis of the femoral head (ONFH) and Avascular osteonecrosis (AVN) – total 86 pts – 60 had both ONFN and AVN. ONFN often b/l more morbidity, raynauds and low vit D compared to AVN Abst#AB0566#EULAR2023 @rheumnow

Bella Mehta bella_mehta ( View Tweet)

Obesity in #AOSD – predicted the development of a chronic disease course and biologic DMARD failure, 139 pts with AOSD- 19% Obese (BMI>30) observational study. abst#AB1503 #EULAR2023 @rheumnow

Bella Mehta bella_mehta ( View Tweet)

Pearls in AOSD – from #EULAR2023 Italian study of 64 patients – AOSD/sJIA pts who achieved drug-free remission more often had white blood cells count >15.000/uL at baseline, however those who were treated with cyclosporine likely failed drug free remission. Abst#AB1484 @rheumnow

Bella Mehta bella_mehta ( View Tweet)

Overview of treatment strategies in #Lupus #EULAR2023 #Rheumtwitter https://t.co/zL1nEDajsb
Christian Ammitzbøll RheumTweeter ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2023 meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

RheumNow Eular 2023 Daily Recap Series https://t.co/oZXuyv8wL5

Links:

Dr. John Cush RheumNow ( View Tweet)

75 different biosimilars in Europe, and nearly 20 years since the journey started. @EMA_News has led the world on biosimilars #EULAR2023 @RheumNow https://t.co/LFs3FR9dfW
David Liew drdavidliew ( View Tweet)
Would you rather have Erosive hands OA or RA? 130+ EHOA and 370+ RA, dis duration > 10 yrs for both cohorts 📍EHOA associated w/ > pain & functional impairment 📍RA associated w/ > comorbidities @RheumNow #EULAR23 POS0103 https://t.co/KdDG7E6PZw
Aurelie Najm AurelieRheumo ( View Tweet)
A model predicts development of PsA in PSO cohort at 1 yr w/ AUC 72.3 Risk factors: ✔️younger age ✔️male ✔️family hx of PSO ✔️back stiffness ✔️nail pitting, ✔️stiffness ✔️PGA ✔️bioDMARDs 5yr prediction model AUC 75 Promising but to be confirmed @RheumNow #EULAR23 POS0019 https://t.co/boCYOH2sDS
Aurelie Najm AurelieRheumo ( View Tweet)
@RheumNow hard at work, shooting KOL videos, at #EULAR2023 https://t.co/C9n2218oeU
Dr. John Cush RheumNow ( View Tweet)
ANSWER cohort Retrospective study 6600+ bio/tsDMARDs ttmt courses, 20 yrs ✔️IL-6Ri is the lowest discontinued for lack of efficacy ✔️CTLA4-Ig is the lowest discontinued due to AEs ✔️Concomitant GC ⬆️30% drug discontinuation due to AEs @Rheumnow #EULAR23 POS0051 https://t.co/8e6U5KHmX4
Aurelie Najm AurelieRheumo ( View Tweet)
The risk of osteoarticular infection following Staph aureus bacteremia is twice higher in RA (1/4) than non RA pop (1/8) Use of TNFi & orthopedic implants associated w/ OAI risk Mortality however similar in RA and non RA groups @RheumNow #EULAR23 POS0033 https://t.co/H6JYkbNu0B
Aurelie Najm AurelieRheumo ( View Tweet)
Always great to have @EMA_News to come and to talk to us at #EULAR2023 Our meds are very important to us, and the more we can understand how decisions are made and RWE is collected, the better 👍 @RheumNow https://t.co/hSutraUsFD
David Liew drdavidliew ( View Tweet)
#EULAR2023 #POS0112 Consistent with clinical response, Post-hoc analyses of Phase 2 RCT of Deucravacitinib (Tyk2-i) showed this therapy suppressed both IFN and B cell pathways - a broader mode of action in reducing #SLE pathophysiology. Look forward to Phase 3 results @RheumNow https://t.co/UoZ2xS3IzC
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
NYU's star rheumatologist, Dr. Jose Scher, wit on the fly at #EULAR2023 https://t.co/O9afiVHSV5
Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×